An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Rallybio to Present at the TD Cowen 44th Annual Health Care Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Rallybio Corporation (Nasdaq: RLYB) announced that its CEO will participate in a panel discussion on Orphan Bone & Neuromuscular Diseases at the TD Cowen 44th Annual Health Care Conference. The live webcast can be accessed on Rallybio's website, with a replay available for 30 days.
Positive
None.
Negative
None.
NEW HAVEN, Conn.--(BUSINESS WIRE)--
Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today announced that Steve Uden, M.D., Chief Executive Officer of Rallybio, will participate in a panel discussion, “Orphan Bone & Neuromuscular Diseases,” at the TD Cowen 44th Annual Health Care Conference on Monday, March 4, 2024 at 9:10 a.m. EST in Boston, MA.
A live webcast of the panel discussion will be accessible through the Events and Presentations section of Rallybio’s website at www.rallybio.com. A replay of the webcast will be available for 30 days following each presentation.
About Rallybio
Rallybio (Nasdaq: RLYB) is a clinical-stage biotechnology company with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. Rallybio has built a broad pipeline of promising product candidates aimed at addressing diseases with unmet medical need in areas of maternal fetal health, complement dysregulation, hematology, and metabolic disorders. The Company has two clinical stage programs: RLYB212, an anti-HPA-1a antibody for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT) and RLYB116, an inhibitor of complement component 5 (C5), with the potential to treat several diseases of complement dysregulation, as well as additional programs in preclinical development. Rallybio is headquartered in New Haven, Connecticut. For more information, please visit www.rallybio.com and follow us on LinkedIn and Twitter.
When will Steve Uden, M.D., CEO of Rallybio, participate in a panel discussion?
Steve Uden, M.D., CEO of Rallybio, will participate in a panel discussion at the TD Cowen 44th Annual Health Care Conference on Monday, March 4, 2024, at 9:10 a.m. EST.
Where can the live webcast of the panel discussion be accessed?
The live webcast of the panel discussion can be accessed through the Events and Presentations section of Rallybio's website at www.rallybio.com.
How long will the replay of the webcast be available?
The replay of the webcast will be available for 30 days following each presentation.
rallybio is a privately-held early-stage biotechnology company incorporated in january 2018. our ambition is to create a world-leading biotechnology organization that transforms the lives of patients with devastating disease, built around people with an outstanding track record in pharmaceutical research and development. we will work on highly-promising drug candidates that have strong biological rationales and that can be addressed using the well-validated therapeutic modalities of small molecules, engineered proteins, and antibodies. rallybio’s founders are seasoned leaders from the biopharma industry with a wide breadth of research, development, and financial experience. the company is based in farmington, ct, at the university of connecticut’s technology incubation program. we are assembling a small team of people with an outstanding track record in pharmaceutical research and development to search for and evaluate assets using a series of robust clinical and commercial filters tha